Suggested period of NOAC interruption prior to device surgery according to renal function (modified with permission from Heidbuchel et al.71)
| CrCL (mL/min) . | Dabigatran (h) . | Apixaban (h) . | Rivaroxaban (h) . | Edoxaban (h) . |
|---|---|---|---|---|
| ≥80 | ≥24 | ≥24 | ≥24 | ≥24 |
| 50–80 | ≥36 | ≥24 | ≥24 | NA |
| 30–50 | ≥48 | ≥24 | ≥24 | NA |
| 15–30 | Not indicated | ≥36 | ≥36 | NA |
| CrCL (mL/min) . | Dabigatran (h) . | Apixaban (h) . | Rivaroxaban (h) . | Edoxaban (h) . |
|---|---|---|---|---|
| ≥80 | ≥24 | ≥24 | ≥24 | ≥24 |
| 50–80 | ≥36 | ≥24 | ≥24 | NA |
| 30–50 | ≥48 | ≥24 | ≥24 | NA |
| 15–30 | Not indicated | ≥36 | ≥36 | NA |
CrCl, creatinine clearance; NA, no available recommendations.
Suggested period of NOAC interruption prior to device surgery according to renal function (modified with permission from Heidbuchel et al.71)
| CrCL (mL/min) . | Dabigatran (h) . | Apixaban (h) . | Rivaroxaban (h) . | Edoxaban (h) . |
|---|---|---|---|---|
| ≥80 | ≥24 | ≥24 | ≥24 | ≥24 |
| 50–80 | ≥36 | ≥24 | ≥24 | NA |
| 30–50 | ≥48 | ≥24 | ≥24 | NA |
| 15–30 | Not indicated | ≥36 | ≥36 | NA |
| CrCL (mL/min) . | Dabigatran (h) . | Apixaban (h) . | Rivaroxaban (h) . | Edoxaban (h) . |
|---|---|---|---|---|
| ≥80 | ≥24 | ≥24 | ≥24 | ≥24 |
| 50–80 | ≥36 | ≥24 | ≥24 | NA |
| 30–50 | ≥48 | ≥24 | ≥24 | NA |
| 15–30 | Not indicated | ≥36 | ≥36 | NA |
CrCl, creatinine clearance; NA, no available recommendations.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
